Financing - March 28, 2022
SynAct resolves on a fully guaranteed rights issue of 150 MSEK
The Board of Directors of SynAct Pharma has resolved to carry out a new issue of shares with preferential rights for existing shareholders of approximately 150 million SEK before issue costs, guaranteed to 100 percent. In addition, the Board of Directors may, based on the authorization granted by the annual general meeting on 21 May […]
Clinical Trials - November 30, 2021
SynAct Pharma’s AP1189 meets primary endpoint
SynAct Pharma has announced results from the Phase 2a study of AP1189 in early rheumatoid arthritis (RA) patients experiencing severe disease activity. In this 4-week study, patients treated once-daily with 100 mg AP1189 achieved a significantly greater reduction in mean Clinical Disease Activity Score (CDAI) as compared to placebo, describes the company. Change in disease […]
Clinical Trials - September 24, 2021
SynAct completes patient recruitment to Phase 2a study
SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis. With all patients included into the study, dosing will be concluded in October with the last patient’s safety follow-up visit to be conducted in November, states the company. SynAct therefore anticipates releasing top-line study data by end […]
In a new job - August 16, 2021
SynAct appoints Vice President Finance and Director of Operational R&D
The company has announced the appointments of Patrik Renblad as Vice President Finance and Lise Agersted as Director of Operational R&D. “We are happy to welcome both Patrik and Lise to the SynAct team,” says SynAct’s CEO Jeppe Øvlesen. “Both are important additions as SynAct pushes forward on its bold strategy to become the leading […]
COVID-19 - July 28, 2021
SynAct Pharma announces positive additional trial data
SynAct Pharma has announced additional results from all treated patients in the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency. The study was setup with part 1, where all patients were treated with AP1189, and a part 2, a randomized placebo-controlled study testing AP1189 vs placebo, giving a total of […]
Clinical Trials - November 15, 2020
SynAct Pharma announces Phase 2 data
SynAct Pharma has announced that an independent Data Safety Monitoring Board (DSMB) has reviewed unblinded and validated data from part 1 of the company’s Phase 2a study in patients with rheumatoid arthritis (RA) with high disease activity with the aim to recommend which dose(s) of AP1189 to be brought into part 2 of the study. […]
